Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Down 14.6% in December

Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 8,340,000 shares, a decline of 14.6% from the December 15th total of 9,770,000 shares. Based on an average trading volume of 2,720,000 shares, the days-to-cover ratio is presently 3.1 days.

Revance Therapeutics Trading Down 0.3 %

RVNC stock traded down $0.01 during midday trading on Thursday, reaching $3.27. The company had a trading volume of 657,968 shares, compared to its average volume of 3,107,087. The company has a 50 day moving average of $3.46 and a two-hundred day moving average of $4.53. The company has a market capitalization of $341.36 million, a P/E ratio of -1.69 and a beta of 0.86. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.56.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, sell-side analysts anticipate that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Institutional investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new position in Revance Therapeutics during the second quarter valued at approximately $33,000. Hsbc Holdings PLC acquired a new position in shares of Revance Therapeutics during the 2nd quarter worth $38,000. FORA Capital LLC bought a new position in shares of Revance Therapeutics during the 3rd quarter valued at $54,000. Creative Planning acquired a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $56,000. Finally, Sei Investments Co. boosted its holdings in Revance Therapeutics by 52.5% in the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 7,628 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

RVNC has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "neutral" rating and issued a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Mizuho dropped their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating on the stock in a research note on Tuesday, December 10th. StockNews.com initiated coverage on Revance Therapeutics in a research report on Monday. They set a "hold" rating for the company. Barclays lowered their target price on Revance Therapeutics from $7.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Monday, December 23rd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.